Syndexa Pharmaceuticals Expands Series B1 Financing Round with Investment by MP Healthcare Venture Management, Inc. Brennan CaruthersDecember 30, 2011
GenKyoTex Starts Phase 1 Trial with First in Class NOX inhibitor GKT137831. Dual NOX1/4 Inhibitor Targets Treatment of Diabetic Nephropathy. Brennan CaruthersOctober 31, 2011
F-Star and Merck Serono to Collaborate in the Discovery and Development of Novel Targeted Biologics. Brennan CaruthersSeptember 7, 2011
GenKyoTex raises CHF 18 million in a Series C Venture Financing to develop NOX enzyme inhibitors. Brennan CaruthersMay 24, 2011
Pronota and Molecuence announce collaboration in protein biomarker discovery. Brennan CaruthersFebruary 22, 2011
